Animal Models of Heart Failure: What Is New?

Monnet, Eric; Chachques, Juan Carlos

doi:10.1016/j.athoracsur.2004.04.002

Cited by 87 publications

(88 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Volume and pressure overload, tachycardia‐pacing, and toxic cardiomyopathy in rabbits are the general methods to evaluate the incidence and progression of congestive heart failure (CHF) (Hasenfuss 1998; Muders and Elsner 2000; Monnet and Chachques 2005; Patten and Hall‐Porter 2009; Houser et al. 2012; Haack et al.…”

Section: Discussionmentioning

confidence: 99%

“…These models are, however, unsuitable for the study of ischemic HF caused by coronary artery diseases. Coronary artery occlusions from the suture ligations, ameroid constrictors, or coiling have been used in mice, rats, rabbits, dogs, and pigs for reproduction of the ischemia‐induced LV dysfunction and HF (Monnet and Chachques 2005; Patten and Hall‐Porter 2009; Dubi and Arbel 2010). In comparison with mouse and rat, the rabbit model allows chronic measurements of hemodynamics, hormonal system, and organ function.…”

Section: Discussionmentioning

confidence: 99%

“…1996; Hunt et al. 2005; Monnet and Chachques 2005; Canty and Suzuki 2012; Houser et al. 2012; Isorni et al.…”

Section: Introductionmentioning

confidence: 99%

“…Various animal models have been developed to investigate different stages of ischemic HF (Hasenfuss 1998; Hearse and Sutherland 2000; Muders and Elsner 2000; Monnet and Chachques 2005; Patten and Hall‐Porter 2009; Schmitto et al. 2011; Huo and Kassab 2015; Camacho et al.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Structure-function remodeling in rabbit hearts of myocardial infarction

Niu

et al. 2017

Physiol Rep

View full text Add to dashboard Cite

Animal models are of importance to investigate basic mechanisms for ischemic heart failure (HF). The objective of the study was to create a rabbit model through multiple coronary artery ligations to investigate the postoperative structure‐function remodeling of the left ventricle (LV) and coronary arterial trees. Here, we hypothesize that the interplay of the degenerated coronary vasculature and increased ventricle wall stress relevant to cardiac fibrosis in vicinity of myocardial infarction (MI) precipitates the incidence and progression of ischemic HF. Echocardiographic measurements showed an approximately monotonic drop of fractional shortening and ejection fraction from 40% and 73% down to 28% and 58% as well as persistent enlargement of LV cavity and slight mitral regurgitation at postoperative 12 weeks. Micro‐CT and histological measurements showed that coronary vascular rarefaction and cardiac fibrosis relevant to inflammation occurred concurrently in vicinity of MI at postoperative 12 weeks albeit there was compensatory vascular growth at postoperative 6 weeks. These findings validate the proposed rabbit model and prove the hypothesis. The post‐MI rabbit model can serve as a reference to test various drugs for treatment of ischemic HF.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…1996; Hunt et al. 2005; Monnet and Chachques 2005; Canty and Suzuki 2012; Houser et al. 2012; Isorni et al.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Structure-function remodeling in rabbit hearts of myocardial infarction

Niu

et al. 2017

Physiol Rep

View full text Add to dashboard Cite

show abstract

“…This drug is usually administered by intravenous or intracoronary injection. The latter allows delivery of DOX at a smaller dose to induce HF without systemic toxicity [203].…”

Section: Non-genetically Engineered Rodent Modelsmentioning

confidence: 99%

Rodent models of heart failure: an updated review

et al. 2012

View full text Add to dashboard Cite

Heart failure (HF) is one of the major health and economic burdens worldwide, and its prevalence is continuously increasing. The study of HF requires reliable animal models to study the chronic changes and pharmacologic interventions in myocardial structure and function and to follow its progression toward HF. Indeed, during the past 40 years, basic and translational scientists have used small animal models to understand the pathophysiology of HF and find more efficient ways of preventing and managing patients suffering from congestive HF (CHF). Each species and each animal model has advantages and disadvantages, and the choice of one model over another should take them into account for a good experimental design. The aim of this review is to describe and highlight the advantages and drawbacks of some commonly used HF rodents models, including both non-genetically and genetically engineered models, with a specific subchapter concerning diastolic HF models.

show abstract

The Role of Translational Medicine and Predictive Biomarkers in the Development of Novel, Innovative Treatments for the Management of Chronic Heart Failure:APharmaceutical Industry Perspective

Douglas¹,

Feuerstein²

2010

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

Chronic heart failure (CHF) represents one of the few cardiovascular diseases with an incidence that continues to rise. While the socio‐economic burden associated with this malignant disease remains high, recent attempts to develop novel, differentiated therapies for the management of CHF (ET‐1, TNFα, dual ACE/NEP inhibitors) have met with failure due to lack of differentiated efficacy and/or safety concerns. Such disappointments have drawn attention to the difficulties faced today in (a) the selection of the most appropriate, innovative targets for the management of this disease; (b) the development of predictive biomarkers that validate the target, define compound pharmacodynamic/‐kinetic (safety/efficacy) relationships, catalog disease modification, and/or assist in patient selection/stratification; and (c) optimal CHF clinical trial design. The present commentary discusses the role of Translational Medicine in the preclinical and clinical CHF Drug Discovery process and details how this emerging scientific discipline can be best used to minimize investment risk/cost.

show abstract

Animal Models of Heart Failure: What Is New?

Cited by 87 publications

References 74 publications

The Structure-function remodeling in rabbit hearts of myocardial infarction

The Structure-function remodeling in rabbit hearts of myocardial infarction

Rodent models of heart failure: an updated review

The Role of Translational Medicine and Predictive Biomarkers in the Development of Novel, Innovative Treatments for the Management of Chronic Heart Failure:APharmaceutical Industry Perspective

Contact Info

Product

Resources

About